Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Parkinsons disease is a dynamic issue that is brought about by degeneration of nerve cells in the part of the cerebrum called the substantia nigra, which controls development. These nerve cells pass on or become weakened, losing the capacity to create a significant chemical called dopamine. Studies have indicated that side effects of Parkinsons create in patients with a 80 percent or more prominent loss of dopamine-delivering cells in the substantia nigra. Levodopa is frequently viewed as the highest quality level of Parkinsons treatment. Levodopa works by intersection the blood-cerebrum barrier, the intricate meshwork of fine veins and cells that filter blood arriving the brain, where it is converted over into dopamine. Bromocriptine, pergolide, pramipexole and ropinirole are prescriptions that copy the job of chemical dispatchers in the cerebrum, making the neurons respond as they would to dopamine.

 

  • Track 1-1Tremor
  • Track 1-2Levodopa
  • Track 1-3Bradykinesia
  • Track 1-4Motor Fluctuation
  • Track 1-5Rigidity

Movement Disorders are a gathering of sensory system conditions that cause anomalous movement, for example fits, yanking or shaking, or, now and again, an absence of movement. Ataxia is a degenerative disorders influencing the brain, brainstem or spinal cord. This can bring about awkwardness, mistake, flimsiness, lopsidedness, tremor or an absence of coordination while performing willful developments. Dystonia results from abnormal working of the basal ganglia, a profound part of the brain which helps control the coordination of movement. These districts of the cerebrum control the speed and ease of movement and avert undesirable movements.

  • Track 2-1Ataxia
  • Track 2-2Dystonia
  • Track 2-3Huntington’s Disease
  • Track 2-4Restless Leg Syndrome
  • Track 2-5Gait Disorders

Parkinsons disease (PD) is one of the most recognized neurologic disorders, influencing roughly 1% of individuals older than 60 years and causing dynamic disability that can be eased back, yet not stopped, by treatment. The epidemiological highlights have been examined in depth, yet the techniques used to move toward the issues have differed extraordinarily, and the outcomes spread a wide scope of components and are commonly uncertain. The rough predominance pace of PD has been reported for to extend from 15 per 100,000 to 12,500 per 100,000, and the frequency of PD from 15 for every 100,000 to 328 per 100,000, with the disease being less normal in Asian countries. The health-related personal satisfaction of PD patients is connected not exclusively to their motor incapacity, but in addition to their non-motor symptoms of depression, sleeping Disorder, bladder, and sexual dysfunction.

  • Track 3-1Age Distribution
  • Track 3-2Neurodegenerative Disorders
  • Track 3-3Gender Differences

Neuromuscular disease is an expansive term that incorporates numerous ailments and disease that disable the working of the muscles. These may straightforwardly include the muscle legitimately or indirectly involve the nerves or the Neuromuscular junction. The indications of Neuromuscular illnesses may incorporate Numbness, Painful abnormal sensation, muscle weakness, muscle atrophy, muscle agony or jerking. Muscular dystrophy is a group of more than 30 conditions that lead to muscle shortcoming and degeneration. As the condition advances, it gets more diligently to move. At times, it can influence breathing and heart work, prompting perilous inconveniences.

  • Track 4-1Multiple Sclerosis
  • Track 4-2Muscular Dystrophy
  • Track 4-3Spinal Muscular Atrophy
  • Track 4-4Autoimmune Disorder
  • Track 4-5Motor Neuron Disease

The exact causes aren't completely comprehended, analysts have distinguished attributes that expansion an individual's risk of developing Parkinsons, including sex, age, race, and hereditary factors. In any case, it is significant that by far most of instances of PD are viewed as idiopathic Parkinsons malady. The investigation demonstrated that people with Parkinsons disease were multiple times bound to have a background marked by melanoma. Moreover, individuals with melanoma had multiple times the risk of creating Parkinsons.

  • Track 5-1Orthostatic hypertension
  • Track 5-2Melanoma
  • Track 5-3Neurogenic Orthostatic Hypotension
  • Track 5-4Pseudobulbar Affect (PBA)
  • Track 5-5Executive dysfunction

Mitochondrial dysfunction is the root cause of many diseases that are bewildering in their variety and complexity. They include rare genetic disorders in children, some forms of heart disease, and most likely many cases of Parkinsons disease. Individuals with autism experience difficulty with communication. They experience trouble understanding what other individuals think and feel. This makes it difficult for them to convey what needs be, either with words or through motions, outward appearances, and contact.

  • Track 6-1Autism
  • Track 6-2Bipolar disorder
  • Track 6-3Mitochondrial complex I inhibitor
  • Track 6-4Peripheral Decarboxylase Inhibitors
  • Track 6-5Mitophagy

Neurosurgery is the careful specialization that treats maladies and disorders of the brain and spinal cord. Back pain can some of the time produce neurological manifestations, for example, deadness, muscle shortcoming, and loss of entrail and bladder control because of dysfunction at the nerve root. Stem cell-based medications are rising as the most encouraging methodology for the advancement of a valuable regenerative treatment that could be utilized in an enormous number of patients. In spite of the fact that progress in this field has been moderate, various energizing clinical preliminaries are currently not too far off, and there is a certifiable expectation that stem cells will enter the center in the short-to-medium-term future.

  • Track 7-1Neural regeneration
  • Track 7-2Subthalamic nucleus
  • Track 7-3Stem cell Therapy
  • Track 7-4Pallidotomy

Neuroimaging is the order that manages the in vivo delineation of anatomy and capacity of the Central Nervous system (CNS) in wellbeing and disease. Diffusion tensor imaging (DTI) is a promising strategy for portraying microstructural changes or contrasts with neuropathology and treatment. The dissemination tensor might be utilized to describe the extent, anisotropy, and direction of the diffusion tensor.

  • Track 8-1Diffusion Tensor Imaging
  • Track 8-2F-18 fluorodeoxyglucose
  • Track 8-3Tc-99m dopamine transporter imaging
  • Track 8-4Magnetic Resonance Imaging

Free radical production and their focused on activity on biomolecules have roles in maturing and age-related disorders, for example, Parkinsons disease (PD). There is an age-related increment in oxidative harm to the brain, and aging is viewed as a hazard factor for PD. The normal connection among aging and PD at the cellular level with unique reference to oxidative damage brought about by free radicals. Oxidative harm incorporates mitochondrial dysfunction, dopamine auto-oxidation, α-synuclein conglomeration, glial cell enactment, modifications in calcium flagging, and overabundance free iron.

  • Track 9-1Neuro Inflammation
  • Track 9-2Progressive Neurodegenerative Disease
  • Track 9-3DNA Degeneration
  • Track 9-4Superoxide radical anion
  • Track 9-5Dopaminergic neurons

Mutations in the protein DJ-1 reason autosomal passive types of Parkinsons Disease (PD) and oxidized DJ-1 is found in the brain of idiopathic PD peoples. While a few capacities have been credited to DJ-1, its commitment to PD pathogenesis isn't yet clear. The pertinence of DJ-1 as a PD biomarker is additionally talked about, as are contemplates investigating DJ-1 as a potential remedial objective for PD and neurodegeneration. Monoamine oxidase inhibitors (MAOIs) were the principal sort of stimulant developed. They're successful, however they've by and large been supplanted by antidepressants that are more secure and cause less symptoms.

  • Track 10-1Dopamine Agonists
  • Track 10-2MAO Inhibitors
  • Track 10-3COMT Inhibitors
  • Track 10-4Peripheral Decarboxylase Inhibitors

Clinical Trials are structured by a severe convention or procedure, guaranteeing that new medicines are tried in a controlled manner to limit any hazard to members. The impact of the treatment is deliberately observed and, notwithstanding deciding their viability, information is gathered on security angles, for example, antagonistic responses and communication with different prescriptions. Here and there a preliminary will contemplate the impacts of utilizing a current treatment in various ways, for example, another plan of the medication.

  • Track 11-1Neural Signatures
  • Track 11-2Electrical Impulse
  • Track 11-3Neuronal plasticity
  • Track 11-4Neuromodulation

Cognitive Problems may encounter psychological issues (dementia) and thinking troubles. These typically happen in the later phases of Parkinsons disease. Such cognitive issues aren't very receptive to medication. Depression and emotional changes may encounter melancholy, at times in the beginning periods. Getting treatment for depression can make it simpler to deal with different difficulties of Parkinsons Disease.

  • Track 12-1Cognitive Problems
  • Track 12-2Depression and Anxiety
  • Track 12-3Insomnia
  • Track 12-4Urinary Incontinence

Physiologically, the side effects related with Parkinsons disease are the consequence of the loss of numerous neurotransmitters, most strikingly dopamine. The course of the disease is profoundly factor, with certain patients showing not very many side effects as they age and others whose side effects progress quickly. The motor signs of Parkinsons sickness are thought to bring about enormous part from decrease of dopamine in the basal ganglia. In the course of the most recent couple of years, a large number of the practical and anatomical outcomes of dopamine misfortune in these structures have been recognized, both in the basal ganglia and in related territories in thalamus and cortex.

  • Track 13-1Subthalamic nucleus
  • Track 13-2Dopaminergic neurons
  • Track 13-3Brain Cell Death
  • Track 13-4Bromocriptine